Introduction
Amorphous solid dispersions are an increasingly popular strategy for improving the bioavailability of poorly soluble APIs (Abraham and Crull, 2014; Guns et al., 2011) . In these ASDs, the API exists at a higher Gibbs free energy than the stable crystalline form, has a greater surface area and is intimately mixed with the carrier (usually a polymer). A hydrophilic polymer is frequently used to prevent crystallization and precipitation of the drug in ASD, and it therefore retains a high supersaturation level in the gastrointestinal tract. In spite of years of research in the area, only around 15 commercial products (e.g., Kaletra that use the ASD technique are available on the market (Meng et al., 2017) . This is due to the tendency of such systems towards spontaneous crystallisation and the perception that crystalline drug products are less risky (Davis et al., 2016) . There are many standards of a successful commercial ASD, and it is possible that a single polymer will not fulfil all requirements. Also, the processing/optimization of these amorphous dispersions remains a key challenge. Recently, it has been demonstrated that ternary ASDs, which contain a mixture of two polymers, can be more physically stable and less prone to API recrystallization than binary compositions (Bi et al., 2013; Prasad et al., 2014) .
Itraconazole (ITZ), a potent anti-fungal drug, was selected as a model drug in this study. It has very low aqueous solubility, approximately 1 ng/mL at pH 7 and 4 µg/mL at pH 1 (Peeters et al., 2002) , it is highly lipophilic (cLogP 6.2) and weakly basic (pKa values 2 and 4) but demonstrates excellent biological membrane permeability (Brouwers et al., 2017) . Separate studies have attempted to increase the bioavailability of ITZ by using spray drying (Kumar et al., 2014) , hot melt extrusion (HME) (Janssens et al., 2008; Thiry et al., 2017; Verreck et al., 2003) , and crystalline ITZ nanoparticles (Yang et al., 2010b) . A previous study by our group showed that combinations of HPMCP and Soluplus ® have a significant effect on the stability of spray dried ITZ against recrystallization (Davis et al., 2017) . HME, a continuous and solvent-free processing method, employed for the preparation of ASDs has advanced as a trustworthy, scalable processing technology in the pharmaceutical industry (Douglas et al., 2016a; Douglas et al., 2016b; Radl et al., 2010) . It has been used to prepare different dosage forms, such as; implants, tablets, process intermediates for controlled release and solubility enhancement of therapeutics (Keen et al., 2014; Lenz et al., 2017) , with acceptable process scale-up and product quality control via process analytical technology (PAT). Rapid physical changes are likely to occur during HME, where the drug is intensively mixed, heated and conveyed through the extrusion barrel and then cooled to solidify at ambient temperature (Jani and Patel, 2015) . So, HME of ITZ may produce liquid crystalline ITZ rather than amorphous ITZ (Singh et al., 2016) .
The main aim of this study was to use HME to prepare novel ternary ASDs of ITZ with enhanced aqueous solubility and physical stability. Both HPMCP and Soluplus ® have been used individually as polymeric carriers for extruded ITZ ASDs. However, to our knowledge, the use of a combination of both polymers has not been prepared by HME previously. The model system chosen was ITZ-HPMCP-Soluplus ® . HPMCP is largely water insoluble (at low pH) so HPMCP bound drug will release in the intestine (it is an enteric polymer) and Soluplus ® bound drug will release in the stomach. HPMCP was selected for its ability to stabilise ITZ in the amorphous state through hydrogen bonding. Soluplus ® was also chosen to enhance stability and make processing by HME possible. A Design of Experiment (DoE) approach was employed to optimize the formulation (Table 1) . Detailed physiochemical characterizations using several analytical techniques such as PXRD, DSC, TGA, FTIR spectroscopy and ssNMR were performed to understand the drug-polymer-polymer molecular interactions, confirm the state of ITZ and compare the results with the formerly prepared spray dried formulations. This was supported by dissolution studies after storage for 12 months.
Materials and Procedures

Materials
Itraconazole was purchased from Xi'an Lyphar Biotech Co., Ltd (Xi'an City, China). Shin Etsu, Tokyo, Japan donated hydroxypropyl methylcellulose phthalate, HP-50 grade (HPMCP)) and Soluplus ® was donated by BASF, Ireland.
Preparation of ITZ ASD by hot melt extrusion
A user-defined Design of Experiment (DoE, Design-Expert ® Software Version 10 -Stat-Ease, Cambridge, United Kingdom) was employed to study the effect of formulation variables (17 combinations: Table 1 ) on the properties of the extruded ASD and provide information on the most effective API-polymer ratios through systematic screening. Drug loading ranged from 10 -30% (w/w) and HPMCP/Soluplus ® ratios varied from 30 -60% (Table 1) .
The ternary solid dispersions were prepared by HME using a 16 mm pharma-lab co-rotating twin screw extruder and L/D ratio of 40:1 (Thermo Fisher Scientific, Karlsruhe, Germany; located at the University of Bradford, UK). The drug and polymers were physically mixed in a polyethylene bag and manually fed into the hopper, while monitoring the motor torque. The processing screw rate was set at 50 rpm and temperatures of the nine-heated barrel and die zones were set as follows: zone 1 = 90 °C, 2 to 4 = 130 °C, 5 to 6 = 155 °C and 7 to 9 = 165 °C. A die with 2.5 mm diameter was fitted at the end of the barrel. After cooling at ambient conditions, the extrudates were milled for a short period of time to avoid heating of the samples (1 to 3 min) using a Mixer Mill, MM 400 (Retsch GmbH, Germany) at 20 Hz frequency, then passed through sieves (particles with diameter < 100 μm were collected) and stored (room conditions:
∼20°C/50% RH) in glass vessels inside a desiccator for further analysis. The DSC analysis confirmed that it is not possible to prepare ASDs of ITZ/HPMCP/Soluplus ® using ball milling only (data not shown here).
Characterisation of ITZ ASDs and pure polymers
2.3.1. Thermogravimetric Analysis (TGA)
TGA was completed using a PerkinElmer TGA 4000 at a heating rate of 10 ºC/min from 20 ºC to 300 ºC under nitrogen purging (50 mL/min). A typical sample weight was 10 mg.
Powder X-Ray Diffraction (PXRD)
PXRD studies of samples were performed before and after storage for 12 months using an Empyrean PANalytical Almelo (The Netherlands) in reflection mode with samples mounted on a spinner configuration using zero background discs. X-rays were generated using Cu anode material and K-α wavelength of 1.5406 Å. The 2θ angle range, step size and dwell time were 5−30°, 0.05°, and 2s, respectively.
Differential Scanning Calorimetry (DSC)
DSC studies were conducted on a Perkin Elmer DSC 8500 equipped with a refrigerated cooling accessory (PerkinElmer, UK). Helium (30 mL/min) was used as the purge gas. The instrument was calibrated using heating rates of 100 and 200 °C/min using high purity indium and zinc to standardize the temperature and heat flow signals. For the glass transition measurement, phosphorus-pentoxide was placed at the bottom of the desiccators to rigorously dry the samples before measurements. 2.0 − 5.0 mg samples were weighed and placed in crimped DSC pans.
Samples were ramped from 0 to 180 °C at 100 °C/min to determine the melt endotherm, or 200 °C/min to study the glass transition region. Analyses was carried out in triplicate using
PerkinElmer Pyris thermal analysis software (version 10.1). 
HPLC method and Dissolution studies
High Performance Liquid Chromatography (HPLC) analysis was performed using an Agilent 1260 Infinity series system (Agilent Technologies, Waldbronn, Germany) equipped with a G1311B 1260 quaternary pump, G1329B 1260 auto-sampler, vacuum degasser and G1316A 1260 temperature-controlled column compartment maintained at 25 °C. The samples were analysed with HPLC at λ = 263 nm using a new method developed for the study and this was accurate and precise for quantification of ITZ in solution along with HPMCP and Soluplus ® (method validation will be described in section 3.8). Four stock solutions of ITZ (250 µg/mL) were prepared in 70%
(v/v) acetonitrile and 30% (v/v) de-ionized water (pH 3 adjusted using ortho-phosphoric acid).
One of the solutions also contained Soluplus ® (1500 µg/mL), one HPMCP (1500 µg/mL) and one with both polymers. A calibration curve was produced using each of the four solutions by continual 1:1 dilution of each solution with mobile phase until no measurable response was attained. Following each dilution, the samples were mixed by vortex, passed through a syringe filter and transferred to amber glass vials until further analysis by HPLC.
A Kromasil C18 5 μm, 4.6 d 250 mm column (MZ-Analysentechnik GmbH, Mainz-Germany) was attached and a flow rate of 1 mL/min was used. An isocratic run, having a total run time of 12 min, was sufficient to separate the ITZ. Typical injection volume was 10 μL. ITZ was detected at a retention time equivalent to 8.8 min at a wavelength of 263 nm. Prior to sample analysis, the developed HPLC method was validated through the evolution of method development and validation parameters including specificity, linearity, precision, limit of detection and limit of quantification. Specificity of the method and peak interference was investigated by injecting a placebo with no ITZ content and no interfering peaks were observed.
Drug release studies were carried out for the ternary ASDs in 900 mL simulated gastric fluid, SGF, (hydrochloric acid at pH 1.2) (Bagavatula et al., 2014) using USP type II apparatus with a paddle speed of 100 rpm at a temperature of 37 ± 0.2 °C. The ASD powders (all containing 150 mg of ITZ) were added to the dissolution medium and 2.5 mL aliquots were withdrawn from each vessel at predetermined time intervals (12, 30, 45 min and 1, 2, 3, 4, 5 and 6 h) with instantaneous replacement of the equivalent volume of the fresh dissolution medium. The samples were passed through a 0.45 µm syringe filter (Teflon) with the first 1 mL of each sample being discarded. A 100 µL aliquot was immediately diluted with 900 μL of the mobile phase to avoid precipitation of the drug.
Results and Discussion
Rationale for polymers selection
The selection of HPMCP and Soluplus ® was based on some key considerations. Firstly, the ease of extrusion of Soluplus ® due to its thermoplastic and rheological properties. Extrusion of HPMCP and ITZ without Soluplus ® was not possible and degradation occurred before the materials exhibited sufficient thermo-plasticisation for extrusion. However Soluplus ® , with its low bulk density and excellent flow properties, has been particularly developed for HME processing with remarkable capabilities for solubilisation of BCS class (II) and a wide possibility of making ASDs (Kolter et al., 2012) . In this study, the addition of Soluplus ® lowered the viscosity of the extrudates, resulting in easier flow of the formulation through the barrel and screws and enabled the extrusion of ternary mixtures containing up to 30% (w/w) ITZ and 40% (w/w) comparison to formulations prepared by spray drying, it is anticipated that both HPMCP and Soluplus ® will form stronger bonds with the ITZ due to the intense mixing/heating during the HME processing (Davis et al., 2017) . As a result, the ITZ can embed itself into the porous structure of the amorphous HMPCP, thus protecting the drug from recrystallization. In addition, compounds are deemed immiscible if the difference in their Hansen's solubility parameters is greater than 7 MPa 1/2 (Greenhalgh et al., 1999) . The previously reported solubility parameters for Soluplus ® and HPMCP are 23.4 and 22.4 MPa 1/2 , respectively, which are very similar to that of ITZ; 22.6 MPa 1/2 (Piccinni et al., 2016) , supporting the suggestion that the ITZ, HPMCP and Soluplus ® are miscible.
Design of experiment (DoE) results
DoE was used to provide a systematic way of selecting the drug-polymer ratios while minimizing the number of formulations required for a statistical analysis. The three factors considered were based on weight percentages (% w/w) of the formulation components: factor A:
ITZ; factor B: Soluplus ® ; and factor C: HPMCP. Formulation parameters were as follows: 10% and that the lowest value of Tg was obtained for the samples containing the highest ratios of ITZ and Soluplus ® e.g. sample 6, 10, 11, 12 and 17.
Thermal stability and processing temperatures
It is essential when producing ASDs using HME to ensure that the API and excipients are thermally stable at the temperatures of manufacturing. . The same trial also indicated that the minimum processing temperature for Soluplus ® was 120 °C so the temperature range for HME zones was selected as 130 °C to 165 °C.
Analysis of crystallinity, PXRD
The crystalline nature of pure ITZ was demonstrated by PXRD patterns with characteristic Bragg peaks at 14.5, 17.7, 20.5, 23.6, 25.5 and 27.3 (Figure 3 ). The patterns were very similar to those reported in previous studies (Lang et al., 2014 Thiry et al., 2016) . However, variation in the drug loading, polymers used and processing methods should be considered for direct comparison.
Thermal analysis, DSC
It is known that the limit of detection of small portions of crystallinity in a mainly amorphous matrix by PXRD is in the range of a few percent crystallinity by mass (Newman et al., 2015) . So, further characterisation was carried out using DSC. Pure crystalline ITZ exhibited a sharp melting endotherm with an onset of 169.46 ± 2.89 °C and a heat of fusion of ΔH = 86.94 ± 3.21 J/g. , is much higher than expected. Glass transition is a structural relaxation governed by a relaxation time, τ. As the thermal conductivities of these polymers are not equal to infinity, there is a lag in the flow of heat through the material during glass transition. Therefore, if the heating rate is increased in magnitude, the available relaxation time is smaller and the transition is shifted to a higher temperature (Moynihan et al., 1974) .
However, it is interesting that the dependence of the Tg of Soluplus ® on heating rate is much greater than that of HPMCP. While thermal conductivity data is not available for these polymers we suggest that the molecular weight of the former being around double that of the latter could be a factor. The quench-cooled ITZ sample, prepared by placing ITZ on a stainless steel hotplate and heating until completely melted before rapidly quenching and grinding in liquid nitrogen exhibited a glass transition at 58.99 ± 0.87 °C (Knapik et al., 2016) . In addition to a Tg, the quench-cooled ITZ displayed two endothermic transitions attributed to the presence of liquid crystals (LCs) (Six et al., 2001 ). The two transitions of liquid crystalline ITZ, TLC1 and TLC2, are located at 74 °C and 90 °C, respectively. This phase transition has been previously reported and confirmed (Singh et al., 2016) . The absence of these endotherms or phase transitions due to liquid crystals in the HME samples indicated that they contained a completely amorphous drug. The DSC scans for ITZ formulations after 12 months of storage at 25°C and 50% RH are illustrated in Figure 4 , and the measured and predicted Tg values are summarised in Table 1 . Each formulation exhibited a single glass transition value regardless of the ratio ( Table 1 ), indicating that the ASDs are present as a homogenous single phase, amorphous drug-polymer-polymer solid dispersion. The ASDs of ITZ prepared by spray drying in our previous study showed two glass transitions corresponding to HPMCP-rich and Soluplus ® -rich amorphous drug phases (Davis et al., 2017) . A single glass transition is preferred in an ASD and therefore, it can be concluded that HME has an advantage over spray drying in preparing the system under investigation by producing more homogenous dispersions and stronger intermolecular interactions.
Theoretical glass transition temperature for each ternary mixture (Tg,mix) was calculated using the Couchman-Karasz (C-K) (Eq. 2) for ternary systems (Couchman and Karasz, 1978) : 3 3 2 2 1 1 3 3 3 2 2 2 1 1 1
where xi is the mass fraction and ΔCpi is the heat capacity change when crossing from the glass to the rubber state in component i and 1, 2 and 3 refer to the three components (3 is assigned to the component with the lowest Tg). The heat capacity change (ΔCp) for pure amorphous ITZ at the Tg was 0.32 J/g°C, and for HPMCP and Soluplus ® equal to 0.31 J/g°C and 0.22 J/g°C, respectively.
From Table 1 (Shen and Torkelson, 1992) .
Conversely, any increase in free volume will act to produce a negative deviation of glass transition temperature from the model. Pennacchia et al. (1986) observed that local compositional fluctuations can also contribute to positive or negative deviations (Pennacchia et al., 1986) . In the case presented here, all experimental Tg values negatively deviated from the predicted values.
However, the interactions between ITZ and polymers in the ternary system are very complex, attributable to the large number and variety of functional groups and size of the polymers where a huge number of intermolecular association permutations are possible.
FTIR spectroscopy
The FTIR spectra ( Figure 5 ) of the raw materials and selected ASD 15 are displayed. In Figure   5 the IR region from 1300/cm to 600/cm is the fingerprint region for ITZ. The peak at 1379/cm is assigned to an ether linkage, R-O-R. Peaks at 1509/cm and 1551/cm are related to R-C=C bonding, and R-C-C bonding, respectively. Peaks at 1451 and 1609/cm are due to the C-N and C=N bonds, respectively and the sharp peak observed at 1697/cm is caused by -C=O stretch of the triazol-3-one moiety in the ITZ (Singh et al., 2016) . The absorption bands between 2831/cm and 3200/cm are attributed to the stretching vibration of (-CH3(vC-H) and amine groups in ITZ (Shim et al., 2006) . For Soluplus ® , peaks around 1638/cm and 1733/cm are related to the carbonyl groups in the vinyl acetate and caprolactam segments (Semjonov et al., 2016 ) and a single carbonyl peak was detected at 1724/cm for HPMCP. Soluplus ® low intensity peak for -OH stretching was observed at 3450/cm. The IR spectra of solid dispersion (ASD 15) shown in Figure 5 ) showed that none of the characteristic peaks of ITZ are evident, confirming the full miscibility of ITZ in the binary polymeric matrix. Among the most distinguished band disappearance happened at 1697/cm (C=O), 1609/cm (C=N), and 1380/cm (C-H of the methyl group) (Yang et al., 2010a) . Also, the disappearance of the -C=O stretch of the triazol-3-one at 1697/cm indicates the formation of H-bonding. Changes in the intensity and position of the absorption band at 2831/cm indicate more chemical interactions between Soluplus ® and ITZ (Zhang et al., 2013) .
Hydrogen bonding in the ternary system will occur between the nitrogen indicated by the arrow in the insert and the carboxylic acid groups in HPMCP. Evidence for hydrogen bonding can be seen by comparing the FTIR spectra of ITZ crystalline with ASD 15. The imine (C=N) stretch present in ITZ crystalline as a strong sharp peak at 1554 cm/cm is absent in ASD 15, indicating that the C=N bond is no longer able to stretch (due to hydrogen bonding). ASD 15 contains ITZ at 30% loading and HPMCP at 40% (w/w), so the hydrogen bonding effect was most noticeable in this sample. The ability of polymers to interact with the API at a molecular level has a significant influence on the properties of the solid dispersions because the intermolecular forces between the components will stabilise the amorphous drug both during storage and whilst maintaining supersaturation in solution.
ssNMR analysis
ssNMR is non-destructive technique which provides qualitative and quantitative information about amorphous solid dispersions. The ssNMR results are shown in the supplementary data (SD2). The 13 C ssNMR spectrum of crystalline ITZ is consistent with that previously published in the literature (Shevchenko et al., 2013; Van Eerdenbrugh et al., 2009) . A broadening of peaks was noted in the spectrum of the ASD, indicating that the components were amorphous. In the NMR spectrum of crystalline ITZ (ASD 17), narrow and sharp peaks are present; these are particularly absent in the 13 C NMR spectrum of the ASD. Differences between the amorphous and crystalline ITZ can be most obviously seen around 152 ppm (one peak for amorphous ITZ in the ASD; three peaks for crystalline ITZ), 146 ppm (one peak for amorphous ITZ in the ASD; two peaks for crystalline ITZ), and 108 ppm (one peak in the ASD; crystalline: two peaks).
Multiple peaks from the HPMCP and Soluplus ® excipients overlapped with those from the spectra of the ASD. Broad peaks with chemical shift(s) nearly matching to those of crystalline ITZ in the 13 C NMR spectrum of the ASD confirm that the ITZ is amorphous. These results are consistent with the powder X-ray diffraction and DSC studies.
In-vitro dissolution
Following and was found to be equal to or less than 0.78%. The limit of detection (LOD) and the limit of quantification (LOQ) were calculated on the basis of the standard deviation of the response and the slope obtained from the linearity plot as described in the relevant ICH guideline (ICH, 1997) .
LOD and LOQ of ITZ were found to be 67.8 ng/mL and 205.5 ng/mL respectively. LOD and LOQ were calculated as 3.3 α/S and 10 α/S respectively, where α is the standard deviation of the y-intercept and S is the slope of the regression line. Results and a statistical analysis of the data suggested that the method is sensitive, selective, reproducible and more precise than the method previously used to measure ITZ (Davis et al., 2017) . Thus, it could be effectively utilized for the routine estimation of the ITZ in various pharmaceutical ASD compositions. For the dissolution studies, it can be seen in Figure 6 that the dissolution of ITZ exhibited a higher release profile from the processed ASDs relative to the crystalline API with ASDs concentration ten-fold higher than crystalline ITZ. While better than crystalline ITZ, the dissolution profiles were relatively low in comparison to a number of other formulations in acidic media and those determined in our previous study. It is likely that the release rate is related to the particle size of the milled extrudate and that the smaller particles prepared by spray drying would achieve faster dissolution (Davis et al., 2017) . The release profiles for selected formulations are presented in Figure 6 showing the comparatively slow and low dissolution efficiency with drug release reaching ∼45% after 6 h in the best case. The dissolution profiles found in this study are very similar to that for the marketed drug Sporanox ® (capsules contain a solid solution of ITZ and hypromellose that is coated on sugar beads produced by Janssen, Belgium). Also, to other formulations containing ITZ and Soluplus ® prepared by Thiry and co-workers, however, it is worth mentioning that the extrudates were not milled (Thiry et al., 2017) . Zhong and co-authors indicated that dissolution of Sporanox ® and other ITZ/Soluplus ® formulations prepared by HME can reach up to 80% in 60 min at pH 1.2 (Zhong et al., 2016) . However, formulations containing ITZ/HPMC had a range of release profiles between 40 to 90% depending on the drug to polymer ratio; the higher the drug content, the lower the release (Six et al., 2001) . So, the relatively slow release reported here can be attributed to the particle size of the milled extrudate and the insolubility of HPMCP at gastric pH. The formulations could be optimized by milling to a smaller particle size distribution or designed to pass through the stomach and release the drug in small intestine. However, this requires further investigation and can be considered for future work.
Concluding Remarks
ITZ-HPMCP-Soluplus ® ternary solid dispersions were successfully developed using HME and significantly enhanced the solubility and bioavailability of ITZ, a poorly water-soluble drug, while 
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